A selection of awards recently earned by Dana-Farber and our staff
U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the
nation’s No. 1 pediatric cancer program in its Best Children’s Hospitals report. This marks the fifth time since the inception of U.S. News’ pediatric specialty rankings in 2009 that Dana-Farber/Boston Children’s has topped the pediatric cancer rankings.
No other program has ranked No. 1 more than twice.
A $20 million gift from the Saverin Family will establish the Saverin Breast Cancer Research Fund at Dana-Farber under the direction of Eric Winer, MD. The Saverin Family’s commitment is the largest individual gift for breast cancer research in Dana-Farber’s history and the family’s first major gift to the Institute. The sole purpose of the gift
is to support research into treatment and eventual cures of advanced or stage IV metastatic breast cancer.
This summer, Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) will implement a new ambulatory transplant program designed to help some stem cell transplant patients avoid hospital stays. Patients who qualify for the program meet key eligibility
criteria and are scheduled to receive a reduced-intensity allogeneic transplant – also known as a “mini transplant.” This modified form uses lower, less toxic doses of chemotherapy and does not require radiation therapy.
Laurie H. Glimcher, MD, president and CEO of Dana-Farber, was elected to membership of the American Philosophical Society (APS). The APS was founded in 1743 by Benjamin Franklin for the purpose of “promoting useful knowledge” and is the oldest learned society in the United States. The APS supports research and discovery through grants and fellowships, lectures, publications, prizes, exhibitions, and public education.
Geoffrey R. Oxnard, MD, and Barbara J. Gitlitz, MD, of USC Norris Comprehensive Cancer Center are co-recipients of the Cancer Community (C2) Catalyst Precision Medicine Award. The honor is presented to individuals that have significantly advanced precision medicine in oncology to bring new, more personalized tests or treatments to patients. Oxnard and Gitlitz, co-principal investigators of the Genomics of Young Lung Study (GOYL), conducted the first study of lung cancer in adolescents and young adults under the age of 40. They found that about 80 percent of the young lung cancer patients had a driver mutation treatable with available targeted therapies or precision medicine.
Avinash Sahu, PhD, is one of three young scientists chosen by the Michelson Medical Research Foundation and the Human Vaccines Project to receive $150,000 each to explore novel approaches toward deciphering how the human immune system fights disease. Sahu, under the guidance of X. Shirley Liu, PhD, at Dana-Farber and Keith T. Flaherty, MD, at Massachusetts General Hospital, is working in cutting-edge research of artificial intelligence (AI) and immuno-oncology.
F. Stephen Hodi, MD, and Eric P. Winer, MD, have been inducted into the 2019 class of Giants of Cancer Care® by OncLive, the official website for the Oncology Specialty Group. They are among 15 oncologists receiving the award, which recognizes individuals selected by their peers for landmark successes within the global field of oncology. Hodi was chosen in the melanoma and other skin cancers category; Winer was named for achievements in breast cancer.
Harvey Cantor, MD, has received the 2019 Excellence in Mentoring Award from the American Association of Immunologists (AAI) in recognition of his exemplary contributions to future generations
of scientists. Cantor is cited for training students and postdoctoral fellows and for his work as the director of NIH-funded postdoctoral training programs in cancer immunology and HIV-related research.
Gordon Freeman, PhD, and another scientist, Clive Wood, PhD, were pronounced co-inventors on a series of cancer immunotherapy patents previously issued to a Japanese researcher
and Japanese drug company. The U.S. District Court ruled that the patents be corrected to name Freeman and Wood as inventors.
Jennifer Crombie, MD, and Samuel Ng, MD, PhD, were recently awarded pilot grants from the Harold and Virginia
Lash Pilot Grant Fund for Lymphoma Research at Dana-Farber. Established in 2018, Crombie and Ng are the first recipients of these philanthropic funds, given to seed novel studies in lymphoma.
Scott Armstrong, MD, PhD, has been selected to receive the 2019 International Society for Stem Cell Research (ISSCR) Tobias Award Lecture. Established in 2015, the award
is supported by the Tobias Foundation and recognizes original and promising basic hematology research, as well as direct translational or clinical research related to cell therapy in hematological disorders.
Karen Fasciano, PsyD, received the Outstanding Clinical Care Award at the 16th American Psychosocial Oncology Society (APOS) Annual Conference. The award recognizes an exceptional psychosocial oncology clinician for outstanding contributions to the field.
The conference focused on the benefits of team-based interdisciplinary oncology, and how treating the whole patient enhances cancer care.
Cigall Kadoch, PhD, is the recipient of the 2019 Martin and Rose Wachtel Cancer Research Award by the American Association for the Advancement of Science (AAAS) and Science Translational
Medicine. The award, which is funded by an endowment courtesy of Martin Wachtel, honors early-career investigators who have performed outstanding work in the field of cancer research. Kadoch will receive $25,000 and is invited to present her research
at the National Institutes of Health. Her essay will also be published in Science Translational Medicine.
Joseph Mancias, MD, PhD, is one of nine recipients receiving the 2019 Damon Runyon-Rachleff Innovation Award. The Damon Runyon Cancer Research Foundation provides an initial
grant of $400,000 over the course of two years to projects that “have the potential to significantly impact the prevention, diagnosis, and treatment of cancer.”
Matthew Meyerson, MD, PhD, has been named the recipient of the 2019 Alfred G. Knudson Award in Cancer Genetics. Meyerson was honored for his work in advancing the understanding
of the genetic basis of lung cancer. The Alfred G. Knudson award is one of two accolades presented annually by the National Cancer Institute (NCI).
Stuart Orkin, MD, has been elected as a council member for the National Academy of Medicine (NAM). Founded in 1970, the NAM is one of three academies that compose the National Academies
of Sciences, Engineering, and Medicine. As a council member, Orkin will help oversee the policies, procedures, funds, and activities of the Academy. He may also consult on a variety of NAM programs and be asked to serve different council-related committees.
Geoffrey Shapiro, MD, PhD, received the Targeted Anticancer Therapies (TAT) Congress’ Cancer Drug Development Award. TAT is an international organization that is part of
the European Society for Medical Oncology (ESMO). The award acknowledges the dedication and achievements of cancer drug development researchers.
Toni Choueiri, MD, and Colleen Feltmate, MD, recently served on a four-member physician panel at Mohammed
Bin Rashid University (MBRU) of Medicine and Health Sciences in Dubai focusing on career opportunities for medical students. The panel discussion enabled medical students at MBRU to learn about career choices from practicing physicians, get advice
on internships, clinical observerships, and research opportunities, and network with panel members.
James M. Cleary, MD, PhD, and Alan D. D’Andrea, MD, are one of seven research teams participating in
the first round of the Pancreatic Cancer Collective’s “New Therapies Challenge.” An initiative of the Lustgarten Foundation and Stand Up To Cancer, the collective aims to improve pancreatic cancer patient outcomes. They collaborate to advance its
diagnosis and treatment, and to support the field’s next investigators.
January – March 2019
The National Cancer Institute (NCI) has extended funding to Dana-Farber and the Broad Institute of MIT and Harvard to generate new models of cancer that more accurately represent human tumors. Dana-Farber and the Broad will serve as one of only two national
Cancer Model Development Centers (CMDC) for cell line model generation as part of the NCI Human Cancer Models Initiative (HCMI). The new contract provides an additional $3,384,000 to create patient-derived cell line models of cancer for another 18
months, until May 2020, bringing the total funding for this project to $7,351,000.
Boston Magazine has named more than 115 physicians and surgeons affiliated with Dana-Farber to its annual "Top Doctors" guide.
The Chan Zuckerberg Initiative (CZI), in collaboration with the Human Cell Atlas (HCA), has selected Dana-Farber to be a member of their Seed Network. The Institute will join the three-year international effort to create a comprehensive reference map
for all human cells.
Eric Fischer, PhD, of the Department of Cancer Biology;
Cigall Kadoch, PhD, of the Department of Pediatric Oncology;
and Andrew Lane, MD, PhD, of the Department of Medical Oncology are recipients of The Mark Foundation’s inaugural Emerging Leader Awards. The foundation awarded a total of eight grants to promising early-career scientists. The awards fund high-risk, high-reward projects to address unmet needs in cancer risk, prediction,
prevention, detection, and treatment. Founded in 2017 by Alex Knaster, The Mark Foundation for Cancer Research is dedicated to accelerating cures for cancer by using a high-impact approach to funding global groundbreaking research. The goal of the
foundation, named in honor of Knaster’s late father, Mark, who succumbed to cancer, is to reward cutting-edge and innovative scientific ideas that attempt to answer the most complex questions about cancer biology.
Xihao (Sherlock) Hu, PhD, is one of four 2019 Parker Scholars selected by the Parker Institute for Cancer Immunotherapy. The recognition is for early career researchers, graduate students, or researchers entering their first postdoctoral appointment.
The scholars focus on novel projects that answer the most critical research questions in cancer immunotherapy. The Parker Institute for Cancer Immunotherapy was established in 2016 by the Parker Foundation to unite the country’s leading immunologists
at top cancer research institutions nationwide.
Charlotta Lindvall, MD, PhD, of Psychosocial Oncology and Palliative Care has been named a 2018 Sojourns Scholar. The Sojourns Scholar Leadership Program is an initiative led by Cambia Health Foundation that identifies and cultivates the next generation of multidisciplinary palliative care leaders, including nurses, physicians,
psychologists, social workers and pharmacists, among others. Lindvall will receive a grant of $180,000 across two years to fund palliative care research projects, supporting her growth as a national leader in the field.
Kathleen Xie, PhD, a postdoctoral fellow in the laboratory of David Pellman, MD, has received a research fellowship from the Helen Hay Whitney Foundation. The fellowship, which runs
for three years, will support her research into how nuclear atypia – the presence of abnormal nuclei in cancer cells – disrupts gene activity. The Helen Hay Whitney Foundation was established in 1947 and aims to increase the number of imaginative,
well-trained, and dedicated medical scientists. It awards approximately 24 research fellowships annually, for a total of more than 1,100 since its inception.
An international team of investigators led by Wendy Garrett, MD, PhD, and Matthew Meyerson, MD, PhD,
has won a Grand Challenge award from Cancer Research UK to tackle the complex issues of how the intestinal microbiome – the mix of helpful and harmful micro-organisms that reside in the colon – influence colorectal cancer development and treatment.
Other Dana-Farber members of the team are Marios Giannakis, MD, PhD; Kimmie Ng, MD, MPH; and Shuji Ogino, MD, PhD. The team will receive up to $25 million (20 million British pounds) over five years from the publicly funded research and awareness charity based in the United Kingdom. The organization’s Grand
Challenge awards fund “international, multidisciplinary teams willing to take on the toughest challenges in cancer.”
Michael Constantine, MD, has been named president of the Massachusetts Society of Clinical Oncologists (MSCO). Founded in 1985, the society assists physicians with their
oncology practices including: research grants, educational seminars, and access to an extensive resource library. Prior to assuming this role, Constantine served as MSCO’s treasurer.
Catherine Hulme-Freudenberger, RN, OCN, has been recognized with a DAISY award, a quarterly honor given to an extraordinary
member of the nursing department. Hulme-Freudenberger has been an infusion nurse at Milford for more than 10 years, and a member of the Integrative Nursing team for the past three years. The DAISY Foundation (Diseases Attacking the Immune System)
established the award in memory of J. Patrick Barnes, whose parents create the foundation in Patrick’s memory after experiencing firsthand the skills, care, and compassion of nurses.
Bruce Johnson, MD, chief clinical officer at Dana-Farber and director of the Center for Cancer Precision Medicine, has been named a co-principal investigator for a five-year grant
awarded by the National Cancer Institute (NCI) Human Tumor Atlas Network (HTAN). The NCI HTAN grant – $12.5 million over five years – will be used to create comprehensive atlases of the molecular and cellular geography that exist in different cancers,
identifying altered cells with pre-malignancy state or tumors that are treatment-resistant. This information will help identify patients who are at-risk for becoming resistant to their existing cancer therapies and develop new treatment options for
them resulting in bench to bedside translational care.
Joseph Mancias, MD, PhD, has been named one of nine 2019 recipients of the Damon Runyon-Rachleff Innovation Award. The award funds cancer research by exceptionally creative
thinkers with “high-risk/high-reward” ideas who lack sufficient preliminary data to obtain traditional funding. Only those scientists with a clear vision and passion for cancer research are selected to receive the prestigious award.
Geoffrey Shapiro, MD, PhD, Institute physician, has been given the TAT 2019 Honorary Award for cancer drug development for his leadership in developmental therapeutics, particularly
in solid tumors. The TAT Honorary Award was established to acknowledge distinguished career drug development experts who have devoted a major part of their careers to the discovery and development of better anticancer medicines.
Elizabeth Stover, MD, PhD, medical oncologist in the Division of Gynecologic Oncology, is a 2019 recipient of the Liz Tilberis Early Career Award from the Ovarian Cancer
Research Alliance (OCRA). The award is for junior faculty with a strong commitment to an investigative career in ovarian cancer research. Each grantee will receive a three-year grant of $150,000 per year.
Philippe Armand, MD, PhD, director of clinical research of the Lymphoma Program, and Lakshmi Nayak, MD,
director of the Center for Central Nervous System Lymphoma, have received grants from the Leukemia and Lymphoma Society (LLS). The funding is part of the society’s $42 million commitment to advance new blood cancer treatment approaches including immunotherapy,
genomics, and precision medicine.
Jennifer Crombie, MD, and Samuel Yao-Ming Ng, MD, PhD, were awarded pilot grants in lymphoma.
Benjamin Ebert, MD, PhD, and Matthew Meyerson, MD, PhD, were elected to the National
Academy of Medicine in recognition of their outstanding professional achievement and commitment to service. It is one of the highest honors in the health and medicine fields, and Ebert and Meyerson are two of 85 newly elected members.
Sarah Hill, MD, PhD, Divya Iyer, PhD, and Issac Klein, MD, PhD, are recipients of the Ann and Sol Schreiber Mentored Investigator Award from the Ovarian Cancer Research Alliance (OCRA). The Award provides a total of $75,000 to be used over one or two
years and will encourage the recipient’s research career in the field of ovarian cancer.
Nina Ilic, PhD, Oliver Jonas, PhD, Elizabeth Stover, MD, PhD, and Adam Sperling, MD, PhD, are four Dana-Farber scientists pursuing research funded by the 2019 endowed Wong Family
Awards in Translational Oncology, which support translational oncology and biotechnology development at the Institute. Aiming to make personalize medicine a reality for all patients, the awards recognize “the most meritorious, innovative, translational
projects that utilize information from multiple platforms to develop new diagnostics, prognostic markers, predictive markers, or therapeutics for cancer.” The Wong Family Awards program began in 2012, and the endowment provides a distribution that
funds the awards annually; the amount for 2019 is $300,000.
October – December 2018
Dana-Farber Cancer Institute and Deerfield Management announced an up to $80 million collaboration to create the Center for Protein Degradation at Dana-Farber. The goal of the Center for Protein Degradation is to interrogate and advance a large portfolio
of advanced targeted protein degrader targets while creating a next-generation protein degrader platform. The new Center for Protein Degradation will be led by Nathanael Gray, PhD,
and Eric Fischer, PhD, while operational support, management expertise, and initial funds will be contributed by Deerfield.
The Pan-Mass Challenge (PMC) announced an unprecedented $56 million gift to Dana-Farber Cancer Institute – exceeding last year’s contribution by a staggering $5 million.
Pasi Jänne, MD, PhD, received an Outstanding Investigator Award from the National Cancer Institute (NCI). Up to $600,000 in direct costs per year for seven years is provided to investigators
to work on projects of unusual potential. Award recipients are cancer researchers who have been nominated by their institutions, have served as a principal investigator on an NCI grant for the last five years, and have demonstrated outstanding research.
Justin Kim, PhD, received the 2018 National Institutes of Health (NIH) Director’s New Innovator Award. Established in 2007, the NIH Director’s New Innovator Award supports unusually innovative
research from early career investigators within 10 years of their final degree or clinical residency who have not yet received a research project grant or equivalent NIH grant. Kim, among 58 other highly distinguished innovative scientists, will receive
funding to further his impact on, and address challenges in relation to, biomedical science.
Eric P. Winer, MD, has received the Susan G. Komen Foundation’s 2018 Brinker Award for Clinical Distinction in Clinical Research. Winer was honored for his seminal contributions in improving
breast cancer treatments, which have helped shape the standard of care for breast cancer patients globally.
Susan Bullman, PhD, and Shekinah Elmore, MD, MPH, have been named as 2018 STAT Wunderkinds. STAT Wunderkinds searches for the most impressive young doctors and researchers in the fields of health and medicine in North America.
Pasi A. Jänne, MD, PhD, received the European Society for Medical Oncology (ESMO) Award for Translational Research. ESMO is the leading organization for medical oncology education
and information committed to offering the best treatment to cancer patients. Established in 1985, the award recognizes excellence in medical oncology advancements within the European and international community and was presented to Jänne for his novel
therapeutic agents in patients with lung cancer.
Giovanni Parmigiani, PhD, was awarded the distinction of Fellow by the American Association for the Advancement of Science (AAAS). Parmigiani, among other individuals,
has been elevated to this rank because of his efforts toward advancing science applications that are deemed scientifically or socially distinguished.
David Weinstock, MD, has been named a 2018 Allen Distinguished Investigator by the Allen Institute. The Allen Distinguished Investigator program funds early stage research that
is less likely to receive support from traditional funding sources but has the potential to significantly advance the understanding of biology. Weinstock, who shares the award with Scott Manalis, PhD, of MIT is studying why some lymphoma patients
are cured but others relapse.
David A. Williams, MD, was awarded the 2018 Karl Landsteiner Memorial Award and Lectureship. Initiated in 1954 to honor the late Karl Landsteiner, the distinction is awarded
annually by the American Association of Blood Banks (AABB) to a scientist whose work has profoundly influenced the fields of transfusion medicine and cellular therapies. Williams was recognized for his work on hematopoietic stem cells and how their
interaction with bone marrow can play a role in stem cell engraftment and mobilization.
William G. Kaelin Jr., MD, received the 2018 Massry Prize and will share the $200,000 award with two other scientists, in addition to receiving a 10-ounce gold medal,
for outstanding contributions to the biomedical sciences and the advancement of health. The three researchers were cited for the discovery of the pathway by which cells from humans and most animals sense and adapt to changes in oxygen availability.
May – September 2018
Members of Dana-Farber’s Legislative Action Network (LAN) played a role in the recent passage of a state law raising the age limit for purchasing tobacco products from 18 to 21.
Dana-Farber faculty, patients, family members, and staff have been active in the coalition of the passing of the Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act. As the most comprehensive childhood cancer bill ever taken up by
Congress, expanded research opportunities may improve efforts to track the disease across populations, and improve the quality of life for pediatric cancer survivors.
Dana-Farber/Brigham and Women's Cancer Center was ranked the highest for cancer care in New England for the 18th straight year, by U.S. News & World Report. This year, Dana-Farber/Brigham and Women’s Cancer Center was ranked #4 in the nation.
Dana-Farber was ranked #7 on Forbes 2018's “America’s Best Mid-Size Employers” list.
Dana-Farber/Boston Children's Cancer and Blood Disorders
Center was named the top pediatric cancer program in New England and #3 in the nation by U.S. News & World Report in its new 2018-19 Best Children's Hospitals report.
Matthew S. Davids, MD, of Medical Oncology,
received the first James O. Armitage Lymphoma Clinical Investigator Award at the Pan Pacific Lymphoma Conference. The conference is one of the largest gatherings of experts in lymphoma and transplantation. This award acknowledges a clinical investigator
whose research shows promise and clinical applicability in the area of lymphoma.
Eliezer Van Allen, MD, of Medical Oncology,
has been awarded a Continuation Grant from the Damon Runyon Cancer Research Foundation. The Continuation Grant provides two additional years of support to Damon Runyon Clinical Investigators in need of additional time and funding for their research.
The $300,000 grant is given over a period of two years.
Benjamin Izar, MD, PhD, has received a Career Award for Medical Scientists from the Burroughs Wellcome Fund. The $700,000 award, given over five years, will support Izar’s research
on understanding mechanisms conferring resistance to immune checkpoint inhibitors.
Caron A. Jacobson, MD, MMS, received a 2018 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). The award is given to outstanding
mid-career clinical investigators at NCI-Designated Cancer Centers (of which Dana-Farber/Harvard Cancer Center (DF/HCC) is one) in recognition of their extensive involvement in NCI-funded collaborative clinical trials.
Cigall Kadoch, PhD, and Paige Malinowski, manager of Dana-Farber's Young Adult Program,
were recently named among the nation’s top “40 Under 40 in Cancer” by The Lynx Group and McGivney Global Advisors. The inaugural award celebrates the contributions individuals under age 40 make to improve the lives of those affected by cancer.
Nancy Lin, MD, of Medical Oncology and Jean Zhao, PhD, of Dana-Farber's Department of Cancer Biology have received a Breakthrough Award from the U.S. Department of Defense to do preclinical testing of drugs known as CDK4/6 inhibitors for breast cancer that has metastasized to the
brain. The research builds on Zhao and her colleagues discovery that the CDK4/6 protein is often deregulated in HER2-positive breast cancer that has spread to the brain.
Alexandre Detappe, PhD, is one of five young cancer researchers selected to receive a Multiple Myeloma Research Foundation (MMRF) Research Fellow Award. Detappe, a postdoctoral research fellow, is currently focused on “Nanoparticle for Early Detection
of Minimal Residual Disease in Multiple Myeloma.”
Lisa R. Diller, MD, has been named a fellow at the Radcliffe Institute for Advanced Study at Harvard University. Each year, the Radcliffe Institute for Advanced Study supports the
work of 50 fellows in the arts, humanities, sciences, and social sciences. Diller will be the 2018-2019 Lillian Gollay Knafel Fellow at Radcliffe, and will be studying the clinical impact of genetic information associated with increased cancer risk
G. Mike Makrigiorgos, PhD, has received two federal grants totaling nearly $3 million for collaborative research aimed at detecting “needle-in-a-haystack” mutations circulating
in the blood of cancer patients. Both grants from the National Institutes of Health (NIH) support innovative methods to boost the detection of tumor DNA in liquid biopsies.
Stuart H. Orkin, MD, has been selected as the recipient of the 2018 Mechthild Esser Nemmers Prize in Medical Science at Northwestern University. This Nemmers Prize is awarded for
achievement and work of lasting significance in the field of medical science. The prize recognizes major contributions to new knowledge or the development of significant new modes of analysis.
Xiao X. Wei, MD, has received a Young Investigator Award from the Kidney Cancer Association. The one-year grant of $50,000 will help fund urology and clinical oncology research, in line
with the Kidney Cancer Association’s goal of improving the lives of those who have been, and will be, diagnosed with kidney cancer.
Judy E. Garber, MD, MPH, and Bruce Johnson, MD, are among 21 inductees of the 2018 Giants of Cancer Care
recognition program. Respected health care professionals were awarded for advancing the field of oncology for their contributions in research and clinical practice.
Lillian M. Guenther, MD, MPH, David Liu, MD, and Harshabad Singh, MD, were three of only five doctors across the country to receive a 2018 Damon Runyon Cancer Research Foundation Physician-Scientist Training Award. The award supports early career physician-scientists
by incentivizing an academic research career with a significant four-year grant for a mentored research project.
Patrick Ott, MD, PhD, Osama Rahma, MD, Catherine Wu, MD,
and Bradley Pentelute, PhD, of the Massachusetts Institute of Technology, have received a Team Science Award from the Melanoma Research Alliance (MRA). The three-year grant, created with funding from BJ’s Wholesale Club, will support their research
into next-generation neoantigen-targeting peptide vaccines for melanoma patients.
Benjamin Ebert, MD, PhD, has been chosen to join the elite cadre of biomedical scientists chosen by the Howard Hughes Medical Institute (HHMI) to receive long-term, flexible
funding as an HHMI Investigator. Ebert is one of 19 new investigators, chosen from 675 eligible applicants, whose selection was recently announced. Each investigator will receive approximately $8 million over a seven-year term that is renewable pending
a scientific review. The new group of investigators is the first to be appointed to a seven-year term – previously it was five years.
Laurie H. Glimcher, MD, president and CEO of Dana-Farber, has received a Lifetime Achievement Award from the American Association of Immunologists (AAI). The award is presented
in recognition of a remarkable career of scientific achievement and contributions to the AAI and the field of immunology.
Shom Goel, MD, PhD, has been awarded a Komen Career Catalyst Research Grant to investigate strategies for overcoming drug resistance in breast cancer treatment. The $450,000 grant from Susan G. Komen® will be used to research why estrogen receptor positive
(ER-positive) breast cancers become resistant to drugs known as CDK4/6 inhibitors that are initially effective against the tumors.
Irene Ghobrial, MD, co-leader of a Stand Up To Cancer (SU2C) Dream Team, was awarded $10 million for a novel project aimed at detecting individuals with precursor conditions before
they develop full-blown multiple myeloma, an incurable blood cancer.
Jennifer Guerriero, PhD, has been awarded a Komen Career Catalyst Research Grant to study drug resistance in triple-negative breast cancer.
Pasi A. Jänne, MD, PhD, is the 2018 recipient of the Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research from the American Association for
Cancer Research (AACR). The award, named for one of the country’s leading experts in head and neck and lung cancer, recognizes worthy cancer researchers, age 51 and under, who have conducted highly meritorious translational and clinical cancer research.
Christopher J. Recklitis, PhD, MPH, has received a SunSmart: Preventing Secondary Skin Cancer in Young Adult Cancer Survivors Award from the Prevent Cancer
Foundation. Funding from the award will enable him and his colleagues to refine and test SunSmart, a video they produced to prevent skin cancer in young adult survivors of cancer by encouraging proper sun protection.
Michal Sheffer, PhD, has won a Stand Up To Cancer (SU2C) Phillip A. Sharp Innovation in Collaboration Award. Sheffer will work with the University Medical Center Utrecht in the Netherlands and young investigator on the SU2C-Dutch Cancer Society Tumor
Organoids Dream Team. Their project focuses on studies of colorectal cancer patient-derived organoids to validate candidate biomarkers of resistance to natural killer cells.
Several Dana-Farber physicians and researchers received awards or were elected to leadership positions during the annual meeting of the American Association for Cancer Research (AACR):
- Institute President and CEO, Laurie H. Glimcher, MD, was elected a Fellow of the AACR Academy, Class of 2018. The AACR Academy recognizes distinguished scientists whose
major contributions have propelled significant innovation and progress against cancer.
- Judy E. Garber, MD, MPH, was elected to serve on the AACR Nominating Committee for the 2018-2020 term. She was also elected by her colleagues in the AACR Academy to serve
as inaugural AACR Academy President-Elect.
- Utthara Nayar, PhD, a research fellow in the laboratory of Nikhil Wagle, MD, received the prestigious AACR Women in Cancer Research Scholar Award.
Twenty-seven Dana-Farber nurses were recognized in the Boston Globe’s annual “Salute to Nurses” supplement, which ran in conjunction with National Nurses Week. The honorees include:
- Paula Buckley
- Cindy Cao
- Carla Chapman
- Virginia Dalton
- Erin Drury
- Lauren Engel
- Katherine Fleming
- Brittney Fontana
- Karen Francour
- Kristen Graham
- Anne Gray
- Jillian Hoffman
- Kathy Houlahan
- Elizabeth Llewellyn
- Jennifer Lowell
- Jen McKenna
- Elizabeth Newins
- Suzanne Oliver
- Courtney Shea
- Robin Sommers
- Despina Stavros
- Kate Stephans
- Ann Stewart
- Jackie Tuskan
- Meghara Walsh
- Annette Werger
- Alyssa Ywuc
2018 Nursing and Patient Care Services (NPCS) Award recipients include:
- Kathleen Bieglagus, BSN, RN, who was presented with the Thomas M. Kloss Nursing Leadership Award, which recognizes a nurse whose work promotes and fosters the Institute’s mission and core values.
- Janette Danowski Hale, RPh, BCOP, who was presented with the Clinician Collaborator in Care Award, which recognizes a non-NPCS clinician who has demonstrated ongoing, consistent support and appreciation for the contribution of nursing and patient
care services in overall achievement of quality patient outcomes over the past year.
- Amy Ferreira, Damon Morris, and Lindsay Speight, who were presented with the Outstanding Clinic Assistant Award, which recognizes clinic assistants whose practice and teamwork has been exemplary over the past year.
- Nancy Grant, RN, OCN, who was presented with the President’s Award for Nursing Excellence, Dana-Farber’s highest nursing honor, which recognizes a DFCI nurse who demonstrates ongoing dedication and commitment to providing the highest quality oncology
care to patients, families, and the community.
- Nane Kouyoumjian and Scott Maidment, who were presented with the Cancer Care Culture of Care Award for Excellence in Patient Experience, which recognizes NPCS staff members whose work promotes and fosters the Institute’s mission and core values.
- Jeanine McManus, BSN, RN, and Cameron Sze, BSN, RN, who were presented with the Award for Excellence in Relationship-Based Nursing Care, which recognizes exemplary relationship-based nursing care practices.
February – April 2018
Dana-Farber has been recognized for the sixth time as a 2018 leader in LGBTQ Healthcare Equality by the Human Rights
Campaign Foundation. Leaders are determined through evaluation by the Healthcare Equality Index (HEI), an annual survey that measures inclusive policies and practices at more than 2,000 medical facilities nationwide.
Dana-Farber’s blog, Insight, won the first-ever Best in Show honor in the Association of American Medical Colleges Group on Institutional Advancement Awards
for Excellence competition. Insight is a hub of information and inspiration for cancer patients, their friends and families, and the general public.
Dana-Farber’s Office of Workforce Development celebrated its 10-year anniversary, and received two citations for “promoting an inclusive workforce
for advancement in the healthcare industry,” and its “commitment to the development of its current and future workforce through programs that increase access and reduce barriers to personal professional and economic development opportunities.” The
two citations were sponsored by Representative Jeffrey Sanchez and Senator Sonia Chang-Diaz.
Lakshmi Nayak, MD, director of the Central Nervous System Lymphoma Center (CNSLC) and senior
physician at Dana-Farber, and an assistant professor of Neurology at Harvard Medical School, has received the 2018 Leukemia and Lymphoma Society Scholar in Clinical Research Award that supports talented blood cancer researchers in the early phase
of their careers. Nayak will receive grants over a period of five years totaling $625,000.
Rosalind A. Segal, MD, PhD, will receive the 2018 Harold Amos Faculty Diversity Award from Harvard Medical School (HMS). The Harold Amos Faculty
Diversity Award was established to recognize faculty who have made significant achievements in moving HMS and the Harvard School of Dental Medicine forward in becoming a more diverse and inclusive community.
Patrick Y. Wen, MD, director of the Center for Neuro-Oncology and Institute Physician at Dana-Farber and
professor of Neurology at Harvard Medical School, was named board president of the Society for Neuro-Oncology.
Eric Fischer, PhD, a member of Dana-Farber’s Chemical Biology Program,
will receive a 2018 Damon Runyon Cancer Research Foundation Innovation Award that funds research on novel approaches to fighting cancer. Fischer is one of 10 early career scientists selected for the Damon Runyon-Rachleff Innovation Award, and will
receive an initial grant of $300,000 over two years. Each awardee will have the opportunity to receive two additional years of funding at the same level.
Myles Brown, MD, and Judy Garber, MD, MPH, have won a grant to investigate a novel strategy aimed at easing the
transition to menopause for women having their ovaries removed because they carry a mutated cancer risk gene.
Constantine Mitsiades, MD, PhD, has received a Stand Up To Cancer (SU2C) Convergence Team Translational Cancer Research Grant for collaborative studies related
to cancer immunotherapy. SU2C announced a total of $11 million to seven multidisciplinary research teams to investigate immune system response to cancers.
Myles Brown, MD, director of Dana-Farber's Center for Functional Cancer Epigenetics,
is a leader of one of eight international scientific teams receiving Prostate Cancer Foundation Challenge Awards aimed at accelerating new and improved treatments for prostate cancer.
Mary E. Cooley, PhD, RN, FAAN, has been chosen by the Oncology Nursing Society, as its first Scholar-in-Residence to work with leadership in creating a new strategic vision for the society’s research agenda.
Lisa Scherber, director of Patient and Family Programs, was honored at the 79th annual Boston Baseball Writer's Dinner with The Sports Museum Lifetime Achievement Award – given each year to a civic or business leader connected to baseball who positively
impacts the Boston community.
Meghan Underhill-Blazey, PhD, APRN, is the recipient of the Oncology Nursing Society’s Victoria Mock New Investigator Award, which is awarded in recognition of her scientific contributions to oncology nursing. It is one of the society’s highest honors.
Three Dana-Farber physicians from our Susan F. Smith Center for Women’s Cancers have been recognized among the top 27 breast oncologists across the
country by Forbes Magazine: Harold Burstein, MD, PhD, a clinician and clinical investigator in the breast oncology center; Ann Partridge, MD, MPH,
co-founder and director of the young women with breast cancer program and head of adult survivorship; and Eric P. Winer, MD, chief of the division of women’s cancers and senior vice
president for medical affairs, have been selected as exemplary leaders in the field of breast oncology.
Six Dana-Farber scientists are pursuing research funded by the 2018 endowed Wong Family Awards in Translational Oncology, which support translational oncology and biotechnology development at the Institute:
Scott Carter, PhD, and Co-PI R. Coleman Lindsley, MD, PhD, who use cutting-edge methods to extract genotyping data from 17,000 tumor samples generated by the Profile research
Andrew Hong, MD, who is harnessing a technology called MITE to characterize all the possible mutations in a cancer gene known as SMARCB1, which can cause a rare, devastating group of
cancers affecting children and young adults.
Seth Wander, MD, PhD, in collaboration with his research mentor Nikhil Wagle, MD, and the Dana-Farber Center for Cancer Precision Medicine, is investigating the molecular causes of resistance
to CDK 4/6 inhibitors in patients with estrogen receptor-positive metastatic breast cancer.
Pablo Martinez, MD, PhD, and Co-PI Chiara Ambrogio, PhD, are studying a family of proteins known as APOBEC enzymes.
November 2017 – January 2018
Boston magazine has named 79 physicians and surgeons affiliated with Dana-Farber to its annual “Top Doctors” guide. Drawing from a Castle Connolly physician database, the list consists of hundreds of Boston-area physicians from many medical specialties.
Following a two-day site visit, surveyors from the American College of Surgeons Commission on Cancer (CoC) have recommended a full three-year re-accreditation with commendation for Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC). Commendation
was given in five areas: clinical research accrual, oncology nursing care, cancer registrar education, Rapid Quality Reporting System participation, and data submission accuracy.
Tobacco Free Mass, a coalition that has advocated for funding and policies supporting tobacco prevention and cessation for 25 years, recently honored Dana-Farber for its longtime commitment to this mission. The coalition acknowledged Dana-Farber’s “continued
leadership role in the fight against tobacco and its harms.”
Nikhil C. Munshi, MD, received an approximately $11 million grant from the National Institutes of Health (NIH) in support of his research program project, Integrative Oncogenomics
of Multiple Myeloma.
Clare Sullivan, BSN, MPH, OCN, clinical program manager of Patient Education, has been appointed to the board of the Cancer Patient Education Network (CPEN), a national interdisciplinary cancer collaborative founded by the National Cancer Institute (NCI)
to strengthen the role of patient education in cancer care.
Gregory Abel, MD, MPH, and R. Coleman Lindsley, MD, PhD, have received two of the inaugural
research grants from the Dresner Foundation’s Myelodysplastic Syndrome (MDS) Research Fund. The awards support cutting-edge MDS research and related programs to improve future standards of care and ultimately lead to a cure.
Amanda Balboni Iniguez, PhD, a postdoctoral fellow at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, has received the Damon Runyon-Jake Wetchler Award for Pediatric Innovation for her work studying mechanisms of drug resistance in childhood
Paul Nuccio, RRT, FAARC, director of pulmonary services at Brigham and Women’s Hospital and Dana-Farber, received a Lifetime Achievement Award for his years of service to the respiratory therapy profession. Nuccio received the award at the annual meeting
of the Massachusetts Society for Respiratory Care.
Heather Parsons, MD, MPH, has been awarded a three-year postdoctoral fellowship to identify, through changes in circulating tumor DNA, causes of treatment resistance in patients
with HER2-positive metastatic breast cancer. Her research is supported by a grant from Susan G. Komen®.
Ann Partridge, MD, MPH, received the 2017 Edward J. Benz Jr. Award for Advancing the Careers of Women Faculty. The award, previously known as the Advancing the Careers of Women
Faculty Award, was announced by the Office for Faculty Development and Committee for Women Faculty. It was renamed in 2017 to honor the legacy of the former Dana-Farber president and CEO.
Stephen Sallan, MD, received Camp Casco’s first-ever Friend for Life Award during its annual benefit event. The award is given to an outstanding individual whose efforts have deeply
impacted the childhood cancer community. Sallan was recognized for his work in progressing the treatment of acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer.
Andrew Aguirre, MD, PhD, and Andrew Lane, MD, PhD, both of Medical Oncology, are among this year’s recipients
of Clinical Scientist Development Awards from the Doris Duke Charitable Foundation. The awards, which provide $495,000 in research support over three years, are presented to junior scientists who have distinguished themselves by the rigor of their
research and their commitment to future excellence as independent clinical researchers.
Institute scientists were among the recipients of the first Xconomy Awards, honoring people who lead innovation in the Boston life sciences community. David Livingston, MD,
in collaboration with MIT, was the winner of the Xconomy Big Idea Award was the Bridge Project, which fosters collaboration between cancer researchers from MIT and Harvard-affiliated hospitals and schools in addressing challenging problems in cancer
research and care. The recipient of the Xconomy Award in Patient Partnership was Dana-Farber’s Nikhil Wagle, MD, for his work in creating the Metastatic Breast Cancer Project, which
collects and sequences DNA from patients’ tumors and looks for genetic changes that are associated with patients’ response, or lack of response, to treatment.
Dana-Farber Cancer Institute President and CEO, Laurie H. Glimcher, MD, was honored by the AAMC (Association of American Medical Colleges) with the prestigious Award for
Distinguished Research in the Biomedical Sciences at a special presentation during the AAMC annual meeting in Boston. The AAMC cited her numerous discoveries that have advanced treatments for several diseases and chronic conditions, including cancer,
asthma, and osteoporosis.
George Canellos, MD, received a Hope Funds for Cancer Research Award of Excellence in Medicine. The award recognizes outstanding achievements in the fields of basic research,
drug development, medicine, patient support, and philanthropy. Canellos was honored for his work in the development of combination chemotherapy regimens, including one of the first such regimens for breast cancer and one for lymphoma.
William Hahn, MD, PhD, participated in a panel discussion on “The War on Cancer 3.0” as part of the HUBweek Festival. The event provided a forum for Hahn and other prominent cancer
researchers to explore the future of cancer treatment.
Christopher Lathan, MD, MS, MPH, has been recognized as one of 57 local leaders of color in the life sciences and health care sectors. The list was compiled by Get
Konnected, a group launched by Colette Phillips, who runs a communications and marketing firm in Boston.
Patrick Wen, MD, has been elected president of the Society for Neuro-Oncology (SNO). The society is the premier North American organization for clinicians, basic scientists, nurses, and
other health care professionals focusing on central nervous system tumors in children and adults. Mark Kieran, MD, PhD, will become the pediatric representative to the SNO board,
and Ian Dunn, MD, will be the neurosurgical representative. The newly elected members will assume their positions following the SNO annual meeting later this month.
August – October 2017
Dana-Farber/New Hampshire Oncology-Hematology has been recognized with a gold award by the New Hampshire Union Leader’s
annual Readers’ Choice program. The satellite facility, based in Londonderry, N.H., was chosen for the highest award in the Cancer Care category by readers who voted online beginning last April.
Dana-Farber’s revamped Redstone Family Vivarium has won the Facility of the Year Award, a TurnKey Award from ALN Magazine, which reports on research facilities. A Vivarium management team was also the recipient of the Partners in Excellence Award for
Leadership and Innovation for incorporating energy saving features, development of electronic record applications, and providing systems that improve research functions.
Jacqueline S. Garcia, MD, has received a $600,000 translational research grant from the Leukemia & Lymphoma Society (LLS) through its Translational Research Program to
support an investigator-initiated, Cancer Therapy Evaluation Program/Experimental Therapeutics Clinical Trials Network sponsored phase 1 study of a two-drug combination for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome.
Lindsay Frazier, MD, is a co-leader of an international effort to improve care and outcomes for children with cancer in low- and middle-income countries. She was one of 45 experts
from 16 countries who met in Toronto in early September to chart a course for convincing governments to scale up effective interventions for childhood cancer worldwide. The experts are working in groups to develop an investment case for funding management
of childhood cancer as part of a Commission on Sustainable Pediatric Cancer Care to be launched by The Lancet Oncology journal in 2018.
Ann Partridge, MD, MPH, has received the 2016 Carol Friedman Award from the Centers for Disease Control’s (CDC) Division of Cancer Prevention and Control (DCPC). The prestigious
award is given annually by the CDC to a “champion of comprehensive cancer control who has made a substantial commitment by including survivorship activities in cancer control planning.”
The Hope Funds for Cancer Research honored three outstanding individuals with its 2017 Award of Excellence in the areas of basic science, clinical development, and medicine at its annual awards dinner. This year's honoree for Medicine was George P. Canellos, MD, Institute Physician at Dana-Farber and Rosenberg Professor of Medicine at Harvard Medical School.
Robin Antonellis, vice president of Human Resources, was elected to the board of directors of the New England Employee Benefits Council, where she will serve a three-year term.
Benjamin Ebert, MD, PhD, was named the recipient of the 2017 William Dameshek Prize from the American Society of Hematology (ASH) for his seminal discoveries in multiple
areas of non-malignant and malignant hematology.
Glorian Sorensen, PhD, is the recipient of the 2017 Mark Dundon Research Award from the Health Enhancement Research Organization (HERO). Her selection recognizes research throughout
her career that advances the science of employee health and well-being.
The American Thyroid Association (ATA) has awarded research grants to Glenn J. Hanna, MD, and Jens Lohr, MD, PhD.
Both grants are funded by the Thyroid Cancer Survivors’ Association Inc. Hanna’s grant from the ATA supports his research whose aim is to discover predictors of response or resistance to immunotherapy treatment with checkpoint inhibitor drugs, which
have shown clinical benefit in a small number of patients with advanced thyroid tumors. Lohr, of Medical Oncology, will study whether testing a “liquid biopsy” from a vial of blood can effectively measure the response to treatment of a patient with
Wendy Gettleman, vice president of Facilities Management and Real Estate, was named one of the 15 Women of FIRE (Finance, Insurance, and Real Estate), by Banker & Tradesman.
Nikhil Wagle, MD, was designated for funding from the AVON 39 The Wall to End Breast Cancer. Wagle will receive $150,000 in 2017, with a possibility of an additional year of funding at the
same level in 2018 for his project to study the development of treatment resistance in estrogen receptor-expressing (ER+) metastatic breast cancer.
Seven Dana-Farber researchers in Pediatric Oncology – Pratiti Bandopadhayay, PhD, MBBS; Brian Crompton, MD;
Christine Duncan, MD; A. Lindsay Frazier, MD; Brenton Mar, MD, PhD;
Kimberly Stegmaier, MD; and Loren Walensky, MD, PhD – have received grant awards from the St. Baldrick’s
Foundation this year. The seven grants, which together total more than $1.6 million, will support various pediatric oncology projects ranging from identifying new drug targets and conducting pre-clinical testing of promising agents to studying long-term
May – July 2017
U.S. News & World Report has ranked
Dana-Farber/Boston Children's Cancer and Blood Disorders Center the nation's #2 pediatric cancer program in its new 2017-18 Best Children's Hospitals report.
Dana-Farber has been named to Becker’s Hospital Review’s 2017 list of 100 Great Hospitals in America. The hospitals on the list are recognized for having a strong history of innovation, providing superior care to patients, and leading clinical advancement
with cutting-edge research.
A $4.6 million grant from the Massachusetts Life Sciences Center (MLSC) will help subsidize Dana-Farber’s massive expansion of its advanced facility for developing and making cell therapies to treat cancer and other diseases. The project will make the
Connell and O’Reilly Families Cell Manipulation Core Facility (CMCF) one of the largest
academic centers for manufacturing therapies that rely on modifying cells under highly controlled conditions.
Irene Ghobrial, MD, director of Dana-Farber’s Michele and Stephen Kirsch Laboratory, has received the 2017 Ken Anderson Award from the International Myeloma Society for her research in multiple myeloma. The
award, which honors the contributions of Ken Anderson, MD, director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma at Dana-Farber,
is given to a scientist under age 45 to recognize and stimulate excellence in myeloma research.
Michael Goldberg, PhD, assistant professor of Cancer Immunology and Virology at Dana-Farber,
is one of nine recipients of Harvard Medical School’s (HMS) 2017 Dean’s Community Service Awards. The award, established in 1999, recognizes individuals who have made outstanding personal efforts in serving the local, national, or international community.
Goldberg received the honor for his work with Camp Casco, a free weeklong summer camp for pediatric cancer patients and survivors.
Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology and scientific director of the Belfer Center for Applied Cancer Science,
is one of two investigators from the National Comprehensive Cancer Network Member Institutions to receive a grant through a collaborative scientific research relationship with AstraZeneca to further evaluate the clinical effectiveness of osimertinib
in the treatment of epidermal growth factor receptor-positive (EGFRm+) non-small cell lung cancer (NSCLC).
Paul G. Richardson, MD, received the prestigious 15th annual Robert A. Kyle Lifetime Achievement Award for advances in research, treatment, and care of multiple myeloma patients. The award, named for renowned
myeloma pioneer Robert Kyle, MD, was presented at a ceremony during the organization’s annual International Myeloma Working Group Summit in Madrid.
Gordon Freeman, PhD, Dana-Farber molecular biologist and immunologist, has been awarded the 2017 Warren Alpert Foundation Prize for transformative discoveries in the field of cancer immunology. Freeman
and four other scientists are sharing the $500,000 prize, given in association with Harvard Medical School (HMS), that recognizes “seminal discoveries that hold the promise to change our understanding of disease or our ability to treat it.”
Laurie H. Glimcher, MD, Dana-Farber President and CEO, is ninth in this year’s ranking of the 50 Most Influential Physician Executives and Leaders compiled by Modern Healthcare, a leading provider of
news and information on the health care industry.
Holcombe Grier, MD, of
Pediatric Oncology, received the Distinguished Career Award from the American Society of Pediatric Hematology/Oncology (ASPHO) at its annual
meeting in Montreal.
Rafael Irizarry, PhD, of
Biostatistics and Computational Biology, has won the 2017 Benjamin Franklin Award for Open Access in the Life Sciences.
The award, presented by bioinformatics.org, an online community of biostatisticians and computational biologists, recognizes an individual who has, in his or her practice, promoted free and open access to the materials and methods used in the life
Pasi A. Jänne, MD, PhD, director of the
Lowe Center for Thoracic Oncology and scientific director of the
Belfer Center for Applied Cancer Science, has been awarded a five-year renewable Clinical Research Professorship
from the American Cancer Society. The grant will support his work in integrating laboratory and clinical research to develop and evaluate new combinations of therapies for genetically distinct subtypes of lung cancer.
Stuart H. Orkin, MD, a researcher at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, whose accomplishments have been recognized with a major German prize and membership in an historic American
society, was elected to the American Philosophical Society (APS), which was founded by Benjamin Franklin in 1743 and was the nation’s first learned society. Orkin was also honored at one of Germany’s oldest and most renowned universities with the
2017 Clotten Foundation Prize for unique contributions to the understanding and treatment of cancer with a particular emphasis on children.
Michael Reney, Dana-Farber senior vice president for finance and chief financial officer (CFO), is listed among 150 Hospital and Health System CFOs to Know by the industry publication Becker’s Hospital Review.
Matthew Meyerson, MD, PhD, and
Ramesh Shivdasani, MD, PhD, have been funded by the Neuroendocrine Tumor Research Foundation as part of a $4 million collaborative grant program. The projects are focusing on how and why neuroendocrine
cells, which are found throughout the body, become cancerous and form carcinoid, pancreatic, and related neuroendocrine cancers.
Justin Brown, PhD, a research fellow in Population Sciences and Gastrointestinal Oncology at Dana-Farber, has received the inaugural National Institutes of Health (NIH) Early-Stage Investigator Award. The award recognizes early-career prevention scientists
who have not competed successfully for a substantial NIH-supported research project before the award nomination submission deadline, but who have already made significant, outstanding research contributions to their respective fields and are poised
to become future leaders in prevention research.
Judy Garber, MD, received the Joseph H. Burchenal Memorial Award, presented for outstanding achievement in clinical cancer research at the annual meeting of the American Association for Cancer Research (AACR).
The award is named for the late Joseph H. Burchenal, MD, a pioneer in the development of chemotherapeutics for the treatment of cancer.
Pasi A. Jänne, MD, PhD, scientific director of the Belfer Center for Applied Cancer Science and director of the Lowe Center for Thoracic Oncology, and Alice Shaw, MD, PhD, director of the Center for Thoracic Cancers at Massachusetts General Hospital,
have been named co-leaders of the Stand Up To Cancer–American Cancer Society Lung Cancer Dream Team.
Eric Winer, MD, of the
Susan F. Smith Center for Women’s Cancers at Dana-Farber, received the 2017 Gianni Bonadonna Breast Cancer Award which recognizes his significant contributions and active clinical and translational
breast cancer research. Dr. Winer has advanced science, improved clinical care and is mentoring the next generation of breast cancer researchers and clinicians.
Three Dana-Farber physicians have been chosen as part of the 2017 class of new members of the American Society for Clinical Investigation (ASCI). They are
Adam Bass, MD, of the
Gastrointestinal Cancer Center;
Rameen Beroukhim, MD, PhD, of the
Center for Neuro-Oncology, and W. Nicholas Haining, MD, BCh, of
Four Dana-Farber scientists have received Outstanding Investigator Awards from the National Cancer Institute (NCI), providing seven years of support for new projects “of unusual potential.” The recipients are
William Kaelin, MD, of
A. Thomas Look, MD, and
Kimberly Stegmaier, MD, of Pediatric Oncology; and
Jean Zhao, PhD, of
Cancer Biology. The awards, which provide up to $600,000 per year in direct costs, were developed in 2014 to give investigators more time than
standard grants allow to break new ground or extend previous discoveries to advance biomedical, behavioral, or clinical cancer research..
Three Dana-Farber physician-scientists have been named to a Stand Up To Cancer (SU2C) Colorectal Cancer Dream Team under a $12 million translational research grant awarded to six institutions in the United States. They are Marios Giannakis, MD, PhD,
the principal investigator of the grant at Dana-Farber; and Nick Haining, BM, BCh, and
Natalie Collins, MD, PhD, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
February – April 2017
Daphne Haas-Kogan, MD, of Dana-Farber's
Department of Radiation Oncology, was elected a member of the Association of American Physicians (AAP). The AAP is a nonprofit, professional
organization composed of members who are leading senior physician scientists and are competitively selected on an annual basis.
Marsha Joselow, LICSW, MSW, was awarded the 2017 Social Work Hospice and Palliative Care Network Award for Excellence in Professional Education.
Ji Li, PhD, and
Heather Parsons, MD, MPH, of Dana-Farber's
Department of Medical Oncology, have been selected as 2017 grant recipients from the Terri Brodeur Breast Cancer Foundation.
Geoffrey Shapiro, MD, PhD, and
Jean Zhao, PhD, are the first recipients of a new program project grant in breast and gynecologic cancer research sponsored by the
Susan F. Smith Center for Women's Cancers. The grant of $500,000 annually for three years is intended to foster research in both breast and gynecologic malignancies - particularly studies that
could potentially lead to clinical trials.
Michael Goldberg, PhD, of Dana-Farber's
Department of Cancer Immunology and Virology, has won a two-year early career award from the Ovarian Cancer Research Fund Alliance
(OCRFA) to study potential immunotherapy strategies for treating ovarian cancer.
Eric Zhou, PhD, is one of four researchers selected to receive a psychosocial grant from Alex’s Lemonade Stand Foundation (ALSF). Awardees of the Psychosocial Launch Grant, designed for early career researchers
whose studies aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer, will receive up to $100,00 over two years.
November 2016 – January 2017
Pediatric Palliative Care Research Network, a multi-center team
of researchers and clinicians working to improve palliative care for children and their families, received a $2 million grant from the National Institute of Nursing Research, which will fund a new cohort study looking at palliative care outcomes for
800 children over the span of two years.
Boston magazine has named 51 physicians and surgeons affiliated with Dana-Farber to its annual Top Doctors Guide. Drawing from a Castle Connolly Medical Ltd. Physician database, the list consists of over 600 Boston area physicians from more than
60 medical specialties and is available on Boston magazine’s website.
Loren Walensky, MD, PhD, faculty member in Dana-Farber's Department of Pediatric Oncology and the Linde Program in Cancer Chemical Biology, and director of the Harvard/MIT MD-PhD program, has been promoted
to professor at Harvard Medical School.
Edward J. Benz Jr., MD, Dana-Farber president emeritus, has received a 2016 SPARK! Award from the Albert Schweitzer Fellowship for his leadership in calling attention to and reducing racial disparities
in cancer care. He was also honored for his leadership in broadening access to high quality cancer care, locally and around the world. He received the first Global Oncology Visionary Award from Global Oncology (GO), a nonprofit committed to reducing
disparities in access to cancer care.
George P. Canellos, MD, received the Robert Kyle Award from the Mayo Clinic for his career contributions to hematologic disease, specifically malignant lymphoma. Canellos also received the John Ultmann
Award at the Lymphoma & Myeloma 2016 meeting in October in New York City.
Gordon Freeman, PhD, of
Medical Oncology, has been named a 2016 Thomson Reuters Citation Laureate for the field of medicine, along with his wife and colleague, Arlene
Sharpe, MD, PhD, of Harvard Medical School and Brigham and Women’s Hospital, and Tasuku Honjo, MD, PhD, of Kyoto University, in Japan. The honor, given by Clarivate Analytics, a computer analysis company, recognizes researchers whose advances are
among the most cited in their field.
Laurie H. Glimcher, MD, president and CEO of Dana-Farber, received the Marion Spencer Fay Award from the Institute for Women’s Health and Leadership at Drexel University in Philadelphia. Given annually,
this award is presented to a woman physician or scientist who has made significant contributions to health care as a practitioner, medical educator, administrator, or research scientist. The award, which includes a $10,000 honorarium, was created
to honor Marion Spencer Fay, a former dean and president of the Women’s Medical College of Pennsylvania.
Charlotta Lindvall, MD, PhD, of
Adult Palliative Care, is one of five winners of an Innovation Challenge issued by the National Quality Forum (NQF), which aims to introduce novel methods to improving quality measurement in health care. Lindvall’s
project, for which she is partnering with surgeons at Brigham and Women’s Hospital and researchers at Massachusetts Institute of Technology, focuses on improving care for palliative surgery patients using natural language processing to mine the electronic
medical record. Lindvall and the other winners will be part of NQF’s first Measure Incubator™ Learning Collaborative, which will connect them with experts, resources, and data to implement their measures nationally.
Ursula Matulonis, MD,has been promoted to professor of Medicine at Harvard Medical School. Matulonis is medical director and program leader of
Gynecologic Oncology at Dana-Farber, interim director of the Susan F. Smith Center for Women's Cancers, and institute physician.
Dana-Farber President Emeritus
David G. Nathan, MD, has been selected for the 2016 Andover Alumni Award of Distinction by the Alumni Council of Phillips Academy.
David Reardon, MD, has been promoted to professor of Medicine at Harvard Medical School. Reardon earned his medical degree from Tufts University School of Medicine, followed by residency and fellowship at
Johns Hopkins Hospital and the University of Michigan.
Timothy R. Rebbeck, PhD, will receive the Joseph F. Fraumeni Jr. Distinguished Achievement Award from the American Society for Preventive Oncology at its 2017 annual meeting.
Deborah Schrag, MD, chief of Dana-Farber's
Division of Population Sciences in Medical Oncology, is the 2016 recipient of the Richard L. Schilsky Cancer and Leukemia
Group B Achievement Award presented by the Alliance for Clinical Trials in Oncology. Established in 2010, the award acknowledges the significant contributions of an individual to cooperative group research.
Steven P. Treon, MD, PhD, has been promoted to professor of Medicine at Harvard Medical School.
Eric Wang, PhD, of Cancer Biology, has received a fellowship grant from the Damon Runyon Cancer Research Foundation, which supports the work of innovative early career researchers across the country. The four-year award will support work by Wang and his
sponsor, Nathanael Gray, PhD, to use chemical biology techniques to identify enzymes and small-molecule inhibitors that enhance the immune system’s ability to detect and destroy emerging tumors.
Susan A. Wills, MBA, CMRP, director of strategic sourcing and contracts at Dana-Farber, earned Fellow status in the Association for Healthcare Resource and Materials Management.
St. Baldrick’s Foundation has awarded more than $1.7 million in grants to scientists at
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center to support research in pediatric cancers. The foundation, a charity that raises money for childhood cancer research,
also awarded three consortium grants totaling nearly $1.5 million to Dana-Farber/ Boston Children’s investigators:
- Christine Duncan, MD, and her team will be supported with $499,605 in funding for research to better understand, prevent, and treat late, organ-specific effects of childhood cancer bone marrow transplantation
in an effort to improve long-term survival.
- Lindsay Frazier, MD, received a grant of $496,614 to lead the Malignant Germ Cell International Consortium (MaGIC) that she created. It is the first multinational consortium addressing this disease,
which is the most common solid tumor in adolescents and young adults. This group includes not only pediatric oncologists, but also the world’s leaders in germ cell tumors from adult oncology, gynecologic, and genitourinary oncology. MaGIC has
already launched three new joint international NCI-funded clinical trials, is evaluating a new diagnostic test that appears to be nearly 100 percent sensitive in detecting relapse, and is investigating the underlying biological causes of this
- Kimberly Stegmaier, MD, will use her grant of $500,000 for research in leukemia, including the first multi-institutional genomics-based precision medicine trial for children with relapsed or very high-risk
leukemias. New technologies will be deployed to sequence all currently known cancer-promoting genes in an individual child’s leukemia. Then, guided by a multidisciplinary group of leukemia experts, treatment recommendations will be made based
upon the genomic findings in the individual child’s leukemia and the availability of a relevant targeted drug for children.
- Rameen Beroukhim, MD, PhD, received a $100,000 grant to study mutations that enable incurable pediatric brain tumors called diffuse intrinsic pontine gliomas (DIPG) to resist current treatments. The funding
will allow Beroukhim and his colleagues to evaluate DIPG specimens from children and determine how the tumors are able to evade treatment, so that more effective treatment strategies can be devised.
- Brian Crompton, MD, was named the “Team Clarkie Fund St. Baldrick’s Scholar,” which provides $75,000 to validate a new targeted therapy approach for Ewing sarcoma, an aggressive bone tumor in adolescents
and young adults. Crompton is also developing a new screening effort to identify additional drug targets in Ewing sarcoma.
- Michael Eck, MD, PhD, received a $100,000 “For the Love of Jack St. Baldrick’s Research Grant” to find new targeted therapies for low-grade astrocytoma brain tumors that are caused by mutations in a protein
called BRAF. The research is intended to develop a detailed understanding of a particular BRAF mutation with the aim of discovering drugs to target this mutation.
August – October 2016
Dana-Farber/Brigham and Women’s Cancer Center has been named the best for cancer care in New England for the 16th straight year, and fourth overall in the country by U.S. News & World Report.
Dana-Farber Cancer Institute has been named to Becker’s Hospital Review’s 2016 list of 100 Great Hospitals in America. The hospitals on the list are recognized for having a strong history of innovation, providing superior care to patients, and leading
clinical advancement with cutting-edge research.
A team led by
Gregory Abel, MD, MPH, a member of the
Division of Population Sciences and the
Division of Hematologic Malignancies at Dana-Farber, has been selected to receive $2.6 million funding from the Patient-Centered Outcomes Research Institute for a five-year clinical trial to determine
if a Shared Care program can be effective in providing quality follow-up care for transplant patients.
Rameen Beroukhim, MD, PhD, received a $100,000 grant from St. Baldrick’s Foundation to study mutations that enable incurable pediatric brain tumors called diffuse intrinsic pontine gliomas to resist current
Brian Crompton, MD, was named the “Team Clarkie Fund St. Baldrick’s Scholar,” which provides $75,000 to validate a new targeted therapy approach for Ewing sarcoma, an aggressive bone tumor in adolescents
and young adults.
Christine Duncan, MD, and her team will be supported with $499,605 in funding from St. Baldrick’s Foundation for research to better understand, prevent, and treat late organ-specific effects of childhood
cancer bone marrow transplantation in an effort to improve long-term survival.
Michael Eck, MD, PhD, received a $100,000 “For the Love of Jack St. Baldrick’s Research Grant” to find new targeted therapies for low-grade astrocytoma brain tumors that are caused by mutations in a protein
called BRAF. The research is intended to develop a detailed understanding of a particular BRAF mutation with the aim of discovering drugs to target this mutation.
Mariella G. Filbin, MD, PhD, a pediatric neuro-oncologist, has won a Burroughs Wellcome Fund Career Award for Medical Scientists. She is among 12 physician-scientists selected for the awards, which provide $700,000 over five years to bridge advanced postdoctoral
or fellowship training and the early years of faculty service.
Lindsay Frazier, MD, received a grant of $496,614 from St. Baldrick’s Foundation to lead a consortium she has created, the Malignant Germ Cell International Consortium. The Consortium is the first multinational
consortium addressing this disease, which is the most common solid tumor in adolescents and young adults.
Laurie H. Glimcher, MD, Dana-Farber’s President and CEO, received the Institute for Women's Health and Leadership's Marion Spencer Fay Award. The national Marion Spencer Fay Award is given annually to
a woman physician or scientist who has made an exceptionally significant contribution to health care as a practitioner, medical educator, administrator or research scientist. The award includes a $10,000 honorarium.
Stephen Hodi, MD, has been promoted to professor of Medicine at Harvard Medical School
William G. Kaelin, MD, Dana-Farber physician-scientist, has been named a winner of the 2016 Lasker Award along with two other scientists for groundbreaking basic research on how the body senses and
adapts to changes in oxygen availability.
Matthew Kulke, MD, has been promoted to professor of Medicine at Harvard Medical School.
Joshua Lakin, MD, of Dana-Farber/Brigham and Women’s Cancer Center, received the Cambia Health Foundation’s two-year, $180,000 grant through the Sojourns Scholar Leadership Program. The Sojourns Scholar
Leadership Program is an initiative designed to advance the next generation of palliative care leaders.
Ann Mullally, MD, of Hematologic Oncology received a research awards from the Damon Runyon Cancer Research Foundation. Mullally’s award was a Continuation Grant for her Damon Runyon Clinical Investigatorship.
Continuation grants, which provide $300,000 over two years, support Runyon clinical investigators who are approaching the end of their original awards and need extra time and funding to complete a promising avenue of research or initiate or continue
a clinical trial developing next generation assays for biological changes in tumors and tracking the emergence of drug resistance.
Geoffrey Oxnard, MD, of Dana-Farber's
Thoracic Oncology Program, recently received a Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). Established in 2009, the awards support outstanding mid-career
clinical investigators at NCI-designated cancer centers who have extensive involvement in NCI-funded collaborative clinical trials and whose leadership and example promote clinical trials and research. He also received a research award from the Damon
Runyon Cancer Research Foundation. As a Damon Runyon Clinical Investigator, Oxnard will receive $450,000 over three years to support his research. The investigatorships are awarded to outstanding early career physician-scientists working under the
mentorship of leading scientists and clinicians across the country.
Michael Reney, Dana-Farber’s chief financial officer (CFO), was named to Becker’s Hospital Review’s 2016 “150 Hospital and Health
System CFOs to Know” list. The annual list features financial executives from for- and nonprofit hospitals and health systems across the country, highlighting the men and women who help their organizations navigate the challenging changes in health
Justin Sanders, MD, MSc, of Dana-Farber/Brigham and Women’s Cancer Center, received the Cambia Health Foundation’s two-year, $180,000 grant through the Sojourns Scholar Leadership Program. The Sojourns
Scholar Leadership Program is an initiative designed to advance the next generation of palliative care leaders.
Alexander Spektor, MD, PhD, radiation oncologist, has won a Burroughs Wellcome Fund Career Award for Medical Scientists. He is among 12 physician-scientists selected for the awards, which provide $700,000
over five years to bridge advanced postdoctoral or fellowship training and the early years of faculty service.
Kimberly Stegmaier, MD, received a grant of $500,000 from St. Baldrick’s Foundation for research in leukemia, including the first multi-institutional genomics-based precision medicine trial for children
with relapsed or very high-risk leukemias.
Eric Wang, PhD, of
Cancer Biology, has received a fellowship grant from the Damon Runyon Cancer Research Foundation, which supports the work of innovative early-career
researchers across the country. The four-year award will support work by Wang and his sponsor, Nathanael Gray, PhD, to use chemical biology techniques to identify enzymes and small-molecule inhibitors that enhance the immune system’s ability to detect
and destroy emerging tumors.
May – July 2016
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center is the nation’s #1 pediatric cancer program, according to the U.S. News & World Report’s 2016-17 Best Children’s
Hospitals rankings. This marks the third year in a row that Dana-Farber/Boston Children’s topped U.S. News’s pediatric cancer rankings. Boston Children’s Hospital remained the best pediatric hospital in the country.
The Harris Poll© ranked the
Jimmy Fund one of the nation's top five strongest brands in the Health Nonprofit category in its 28th annual EquiTrend Study.
Adam Bass, MD, and Charles S. Fuchs, MD, MPH, were honored at the American Cancer Society’s annual Financial Services Cares Gala in New York. Fuchs, director of Dana-Farber’s
Gastrointestinal Cancer Center, and Bass, a physician-scientist at Dana-Farber who does research in stomach cancer and is an associate member of the Broad Institute of MIT and Harvard, received
the Eugene D. O’Kelly Award.
Edward J. Benz Jr., MD, has been selected as a 2016 Innovator in Health by the Network for Excellence in Health Innovation for “his extraordinary innovation in the field of cancer medicine, leadership
in the Boston health care community, and commitment to collaborative care.” He was also named to Massachusetts General Hospital Cancer Center’s “the one hundred.”
Judy E. Garber, MD, MPH, director of Dana-Farber’s
Center for Cancer Genetics and Prevention, has been appointed chair of the Scientific Advisory Board of the Breast Cancer Research Foundation, effective June 1.
William G. Kaelin Jr., MD, has received the 10th annual Princess Takamatsu Award from the American Association for Cancer Research. He also was honored with the ASCO Science of Oncology Award and gave
a lecture discussing new cancer treatments emerging from studies of the VHL tumor suppressor protein and IDH oncoproteins.
Franziska Michor, PhD, received the award for Outstanding Achievement in Cancer Research at the 2016 American Association for Cancer Research Annual Meeting in New Orleans. The award is given to an investigator
younger than 40.
Francesca Noll, RT(T), has been named to Massachusetts General Hospital Cancer Center's "the one hundred."
Kimberly Stegmaier, MD, has been awarded a research grant from The Rally Foundation for Childhood Cancer Research to investigate new potential drug targets in acute lymphoblastic leukemia.
Joanne Wolfe, MD, MPH, division chief of
Pediatric Palliative Care at Dana-Farber and director of Palliative Care at Boston Children’s Hospital, delivered the 2016 Frank A. Oski Lecture at the American Society of Pediatric Hematology/Oncology
annual meeting. The lectureship is awarded annually to an outstanding clinical or laboratory investigator in pediatric hematology/oncology.
September 2015 – April 2016
The Schwartz Center for Compassionate Healthcare recognized Dana-Farber for hosting the Schwartz Center Rounds for more than 10 years.
The Association for the Accreditation of Human Research Protection Programs Inc. has awarded Dana-Farber, on behalf of Dana-Farber/Harvard Cancer Center (DF/HCC), a full five-year reaccreditation.
The Joint Commission concluded a five-day, 90-hour hospital survey. Three surveyors from the Joint Commission lauded Dana-Farber’s care as “the way it’s supposed to be.” They documented excellence at every level, and identified only a few areas for improvement.
Dana-Farber was ranked fourth in the country in NurseJournal.org’s Top 100 Most Social Media Friendly Hospitals for 2014 for having a strong social media presence on Facebook and Twitter.
Dana-Farber has been recognized as a Leader in LGBT Healthcare Equality by the Human Rights Campaign Foundation as a result of its findings from the Healthcare Equality Index 2016, an annual survey that encourages equal care by evaluating inclusive policies
and practices related to LGBT patients, visitors, and employees.
Dana-Farber received an award for greatest electricity reduction in 2015 in Better City’s Seventh Annual Challenge for Sustainability Awards.
Boston magazine has named 60 physicians and surgeons affiliated with Dana-Farber to its annual Top Doctors guide.
Myles Brown, MD, has been elected to the National Academy of Sciences. Brown, who is the director of the
Center for Functional Cancer Epigenetics at Dana-Farber, is one of 84 new members and 21 foreign associates from 14 countries
elected to the Academy in recognition of their distinguished and continuing achievements in original research.
Paul Richardson, MD, clinical program leader and director of clinical research at Dana-Farber/Brigham and Women's Cancer Center's
Jerome Lipper Center for Multiple Myeloma, and RJ Corman Professor of Medicine at Harvard Medical School, received the Multiple Myeloma Achievement Award at
the 2nd World Congress on Controversies in Multiple Myeloma, held in Paris.
Matthew Meyerson, MD, PhD, has received the 2016 Han-Mo Koo Memorial Award from the Van Andel Research Institute (VARI). The award recognizes Meyerson's "immeasurable contributions to the understanding
of cancer genomics and targeted therapies."
Fatih Aydogan, MD, FEBS, a postdoctoral research fellow in the
Susan F. Smith Center for Women's Cancers at Dana-Farber, received the 2015 Conquer Cancer Foundation of the American Society of Clinical Oncology Merit Award. This honor recognizes early-career
oncologists and scientists for their significant research accomplishments.
Amanda Balboni, PhD, and Neil T. Umbreit, PhD, were named Damon Runyon Fellows by the Damon Runyon Cancer Research Foundation at the 2015 Fellowship Award Committee meeting. Fellows are outstanding postdoctoral scientists involved in cancer research in
the labs of leading senior investigators.
The Visiting Nurse Association of Boston honored Dana-Farber President and CEO
Edward J. Benz Jr., MD, as a 2015 Hero in Health Care for leading the Institute’s transformation during his 15-year tenure.
Rachelle E. Bernacki, MD, MS, director of Quality Initiatives in the Division of
Adult Palliative Care, Department of Psychosocial Oncology and Palliative Care, received the Cambia Health Foundation’s two-year, $180,000 grant through the Sojourns Scholar Leadership Program. The grant provides
educational and leadership development opportunities.
Myles Brown, MD; David Livingston, ND;
Ann Partridge, MD, MPH; Remigio Picone, PhD;
Nikhil Wagle, MD;
Eric Winer, MD, will receive a total of $2.28 million in new grants for basic and clinical studies of breast cancer from Susan G. Komen®.
Myles Brown, MD, received the Susan G. Komen® Brinker Award for Scientific Distinction in Basic Science. Established in 1992, the award recognizes the efforts of pioneers in two critically important areas of the fight to end breast cancer: clinical research
and basic science.
Ennio A. Chiocca, MD,PhD, has been elected president of the Society for Neuro-Oncology, an organization representing North American neuro-oncologists and scientists.
Anthony D’Amico, MD, PhD, chief of Genitourinary
Radiation Oncology and an Institute Physician at Dana-Farber, received the Kligerman Award for radiation oncology research from the Perelman School of Medicine at the University of Pennsylvania.
The Association of Pediatric Hematology/Oncology Nurses recently honored Jimmy Fund Clinic nurse Denise Desrochers, RN, CPON, with the Certified Pediatric Oncology Nurse (CPON) of the Year Award. The award recognizes a CPON who has made significant contributions
to pediatric oncology or hematology nursing and who has supported and promoted oncology nursing certification.
Levi Garraway, MD, PhD; Matthew Meyerson, MD, PhD;
Shuji Ogino, MD, PhD;
Kornelia Polyak, MD; and
Loren Walensky, MD, PhD, are among the first group of scientists to receive Outstanding Investigator Awards from the National Cancer Institute. The awards were created last year to provide funding to
cancer scientists with outstanding records of productivity to continue or embark on new projects of unusual potential over an extended period of seven years.
The Li-Fraumeni Syndrome (LFS) Association honored Dana-Farber’s
Judy Garber, MD,MPH, and Katherine Schneider, MPH, LGC, with “Hero” awards for their uncompromised dedication to LFS treatment and research.
Krietta Bowens Jones, associate general counsel at Dana-Farber, has been appointed to a two-year term as co-chair of the Delivery of Legal Services section of the Boston Bar Association.
Shirley Liu, PhD, director of the Center for Functional Cancer Epigenetics at Dana-Farber, and professor of biostatistics and computational biology at the Harvard T.H. Chan School of Public Health, has received the Richard W. Weitzman Outstanding Early
Career Investigator award for her work in the computational modeling of transcriptional and epigenetic gene regulation.
Jessica Lord, benefits compliance and operations manager in Human Resources, won a Rising Star Award at the 2015 New England Employee Benefits Council’s 17th Annual Best Practices Conference. The award recognizes new benefits professionals who have demonstrated
exceptional promise in their field.
The National Institutes of Health is funding collaborative research by Dana-Farber and a biotech company to improve the performance of an invention by
Mike Makrigiorgos, PhD, of Radiation Oncology. Dana-Farber and Transgenomic will be partners under the two-year, $1.5 million NIH Small Business Technology Transfer grant.
Mary McKenney, MSN, NP, was recognized as a CURE Magazine Extraordinary Healer.
Fremonta Meyer, MD, was awarded the Jonathan F. Borus Outstanding Early Career Educator Award in medical student education for 2015. Meyer received the award for her outstanding work and commitment to her
psychiatry students at Dana-Farber and Brigham and Women’s Hospital.
Matthew Meyerson, MD, PhD, was honored as a 2015 Biomedical Research Leader at the annual Biomedical Research Day Honors Luncheon of the Massachusetts Society for Biomedical Research. Meyerson received the honor for his contributions to biomedical research
and education in New England.
Wilfred Ngwa, PhD, of Radiation Oncology, has been awarded a $100,000 Bright Futures Prize to support the development of miniature programmable drone-like particles to fight metastatic cancer.
The Patient-Centered Outcomes Research Institute has given investigators at Dana-Farber and allied institutions a $13.3 million funding award to study treatment options for patients with ductal carcinoma in situ. Ann Partridge, MD, MPH, a senior physician
in the Susan F. Smith Center for Women’s Cancers at Dana-Farber, is the study’s co-principal investigator.
Kornelia Polyak, MD, PhD, of Medical Oncology, received the 14th Rosalind E. Franklin Award for Women in Science at the Annual National Cancer Institute Intramural Scientific Retreat. The award, which honors Franklin’s role in the discovery of the DNA
double helix, recognizes the commitment of women in cancer research.
The American Nurses Association Board of Directors has appointed Patricia Reid Ponte, DNSc,RN, NEA-BC, FAAN, president of the American Nurses Credentialing Center.
Dorothy Puhy, Dana-Farber’s executive vice president and chief operating officer, was honored by the Boston Business Journal’s 2015 WomenUp: Local Women of Influence program. The program recognizes women who have made a difference in their businesses,
industries, and communities.
Kimberly Stegmaier, MD, of
Dana-Farber/Boston Children’s Cancer and Blood DisordersCenter, will receive the 2016 E. Mead Johnson Award in Pediatric Research for her work in discovering new molecular targets
in several childhood cancers and bringing potential treatments to clinical trials. The award, given since 1939 by the Society for Pediatric Research, is conferred on two scientists each year.
Susan Block, MD, an Institute physician in Dana-Farber's
Department of Psychosocial Oncology and Palliative Care, Harvard Medical School professor, and director of the Serious
Illness Care Program at Ariadne Labs, has received the Lifetime Achievement Award at the American Academy of Hospice and Palliative Medicine (AAHPM) Annual Assembly in Chicago. The award is among the highest honors in the field.